Item 8.01 Other Events.
On May 29, 2020, Agios Pharmaceuticals, Inc. (the "Company") issued a press
release announcing updated data from the ongoing phase 1 study evaluating single
agent vorasidenib in isocitrate dehydrogenase-mutant advanced solid tumors,
including glioma. The Company presented data from the non-enhancing glioma
population at the American Society of Clinical Oncology (ASCO) Annual Meeting.
The full text of the press release issued in connection with this announcement
is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 Press release issued May 29, 2020.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses